Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

Providers' Perspectives on Treating Patients With Thalassemia.

Radke T, Paulukonis S, Hulihan MM, Feuchtbaum L.

J Pediatr Hematol Oncol. 2019 Oct;41(7):e421-e426. doi: 10.1097/MPH.0000000000001573.

PMID:
31368920
2.

Newborn Screening for Severe Combined Immunodeficiency and T-cell Lymphopenia in California, 2010-2017.

Amatuni GS, Currier RJ, Church JA, Bishop T, Grimbacher E, Nguyen AA, Agarwal-Hashmi R, Aznar CP, Butte MJ, Cowan MJ, Dorsey MJ, Dvorak CC, Kapoor N, Kohn DB, Markert ML, Moore TB, Naides SJ, Sciortino S, Feuchtbaum L, Koupaei RA, Puck JM.

Pediatrics. 2019 Feb;143(2). pii: e20182300. doi: 10.1542/peds.2018-2300.

3.

Follow-up status during the first 5 years of life for metabolic disorders on the federal Recommended Uniform Screening Panel.

Feuchtbaum L, Yang J, Currier R.

Genet Med. 2018 Aug;20(8):831-839. doi: 10.1038/gim.2017.199. Epub 2017 Dec 7.

PMID:
29215646
4.

Genomic sequencing in cystic fibrosis newborn screening: what works best, two-tier predefined CFTR mutation panels or second-tier CFTR panel followed by third-tier sequencing?

Currier RJ, Sciortino S, Liu R, Bishop T, Alikhani Koupaei R, Feuchtbaum L.

Genet Med. 2017 Oct;19(10):1159-1163. doi: 10.1038/gim.2017.32. Epub 2017 May 4.

PMID:
28471435
5.

Emergency department utilization by Californians with sickle cell disease, 2005-2014.

Paulukonis ST, Feuchtbaum LB, Coates TD, Neumayr LD, Treadwell MJ, Vichinsky EP, Hulihan MM.

Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26390. Epub 2016 Dec 21.

6.

A framework for assessing outcomes from newborn screening: on the road to measuring its promise.

Hinton CF, Homer CJ, Thompson AA, Williams A, Hassell KL, Feuchtbaum L, Berry SA, Comeau AM, Therrell BL, Brower A, Harris KB, Brown C, Monaco J, Ostrander RJ, Zuckerman AE, Kaye C, Dougherty D, Greene C, Green NS; Follow-up and Treatment Sub-committee of the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC).

Mol Genet Metab. 2016 Aug;118(4):221-9. doi: 10.1016/j.ymgme.2016.05.017. Epub 2016 May 31.

7.

Defining Sickle Cell Disease Mortality Using a Population-Based Surveillance System, 2004 through 2008.

Paulukonis ST, Eckman JR, Snyder AB, Hagar W, Feuchtbaum LB, Zhou M, Grant AM, Hulihan MM.

Public Health Rep. 2016 Mar-Apr;131(2):367-75.

8.

Damaged goods?: an empirical cohort study of blood specimens collected 12 to 23 hours after birth in newborn screening in California.

Tang H, Feuchtbaum L, Neogi P, Ho T, Gaffney L, Currier RJ.

Genet Med. 2016 Mar;18(3):259-64. doi: 10.1038/gim.2015.154. Epub 2015 Dec 10.

PMID:
26656653
9.

Newborn Screening for Cystic Fibrosis in California.

Kharrazi M, Yang J, Bishop T, Lessing S, Young S, Graham S, Pearl M, Chow H, Ho T, Currier R, Gaffney L, Feuchtbaum L; California Cystic Fibrosis Newborn Screening Consortium.

Pediatrics. 2015 Dec;136(6):1062-72. doi: 10.1542/peds.2015-0811. Epub 2015 Nov 16.

10.

Undiagnosed metabolic dysfunction and sudden infant death syndrome--a case-control study.

Rosenthal NA, Currier RJ, Baer RJ, Feuchtbaum L, Jelliffe-Pawlowski LL.

Paediatr Perinat Epidemiol. 2015 Mar;29(2):151-5. doi: 10.1111/ppe.12175. Epub 2015 Feb 16.

PMID:
25689231
11.

Population based surveillance in sickle cell disease: methods, findings and implications from the California registry and surveillance system in hemoglobinopathies project (RuSH).

Paulukonis ST, Harris WT, Coates TD, Neumayr L, Treadwell M, Vichinsky E, Feuchtbaum LB.

Pediatr Blood Cancer. 2014 Dec;61(12):2271-6. doi: 10.1002/pbc.25208. Epub 2014 Aug 30.

PMID:
25176145
12.

State-based surveillance for selected hemoglobinopathies.

Hulihan MM, Feuchtbaum L, Jordan L, Kirby RS, Snyder A, Young W, Greene Y, Telfair J, Wang Y, Cramer W, Werner EM, Kenney K, Creary M, Grant AM.

Genet Med. 2015 Feb;17(2):125-30. doi: 10.1038/gim.2014.81. Epub 2014 Jul 3.

13.

Infants suspected to have very-long chain acyl-CoA dehydrogenase deficiency from newborn screening.

Merritt JL 2nd, Vedal S, Abdenur JE, Au SM, Barshop BA, Feuchtbaum L, Harding CO, Hermerath C, Lorey F, Sesser DE, Thompson JD, Yu A.

Mol Genet Metab. 2014 Apr;111(4):484-92. doi: 10.1016/j.ymgme.2014.01.009. Epub 2014 Jan 23.

PMID:
24503138
14.

Developing a public health-tracking system for follow-up of newborn screening metabolic conditions: a four-state pilot project structure and initial findings.

Hinton CF, Mai CT, Nabukera SK, Botto LD, Feuchtbaum L, Romitti PA, Wang Y, Piper KN, Olney RS.

Genet Med. 2014 Jun;16(6):484-90. doi: 10.1038/gim.2013.177. Epub 2013 Dec 5.

15.

Analysis of cases of 3-methylcrotonyl CoA carboxylase deficiency (3-MCCD) in the California newborn screening program reported in the state database.

Lam C, Carter JM, Cederbaum SD, Neidich J, Gallant NM, Lorey F, Feuchtbaum L, Wong DA.

Mol Genet Metab. 2013 Dec;110(4):477-83. doi: 10.1016/j.ymgme.2013.09.006. Epub 2013 Sep 17.

PMID:
24103308
16.

Birth prevalence of disorders detectable through newborn screening by race/ethnicity.

Feuchtbaum L, Carter J, Dowray S, Currier RJ, Lorey F.

Genet Med. 2012 Nov;14(11):937-45. doi: 10.1038/gim.2012.76. Epub 2012 Jul 5.

PMID:
22766612
17.

Biochemical, molecular, and clinical characteristics of children with short chain acyl-CoA dehydrogenase deficiency detected by newborn screening in California.

Gallant NM, Leydiker K, Tang H, Feuchtbaum L, Lorey F, Puckett R, Deignan JL, Neidich J, Dorrani N, Chang E, Barshop BA, Cederbaum SD, Abdenur JE, Wang RY.

Mol Genet Metab. 2012 May;106(1):55-61. doi: 10.1016/j.ymgme.2012.02.007. Epub 2012 Feb 9.

PMID:
22424739
18.

What questions should newborn screening long-term follow-up be able to answer? A statement of the US Secretary for Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children.

Hinton CF, Feuchtbaum L, Kus CA, Kemper AR, Berry SA, Levy-Fisch J, Luedtke J, Kaye C, Boyle CA.

Genet Med. 2011 Oct;13(10):861-5. doi: 10.1097/GIM.0b013e3182209f09.

PMID:
21716119
19.

The context and approach for the California newborn screening short- and long-term follow-up data system: preliminary findings.

Feuchtbaum L, Dowray S, Lorey F.

Genet Med. 2010 Dec;12(12 Suppl):S242-50. doi: 10.1097/GIM.0b013e3181fe5d66.

PMID:
21150370
20.

Questioning the Need for Informed Consent: A Case Study of California's Experience with a Pilot Newborn Screening Research Project.

Feuchtbaum L, Cunningham G, Sciortino S.

J Empir Res Hum Res Ethics. 2007 Sep;2(3):3-14. doi: 10.1525/jer.2007.2.3.3.

PMID:
19385846

Supplemental Content

Loading ...
Support Center